Immunotherapies, Novel Agents in Hepatocellular Carcinoma
This video examines the promise of recent trials studying single-agent immunotherapy as well as ongoing trials testing combinations of immune-checkpoint inhibition.
Anti–CTLA-4 and anti–PD-1 checkpoint inhibitors have both shown promise in the treatment of hepatocellular carcinoma (HCC).
In this video, Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center in New York, discusses the promise of recent trials that have studied single-agent immunotherapy and ongoing trials testing combinations of immunotherapies and immune-checkpoint inhibition in different lines of treatment.
Abou-Alfa also highlights the latest results in second-line HCC treatment using the multikinase inhibitor regorafenib, and looks ahead at trials involving c-MET inhibition for patients with HCC.
